Seeking Alpha

Goldman adjusts Regeneron estimates following Q3 results

  • Goldman's Terence Flynn tweaks his Regeneron (REGN -3.6%) numbers a bit following Q3 results.
  • Flynn's new estimates: FY14 Eylea sales of $1.88B. That's down from $1.98B previously "to reflect single digit growth in H1 2014 (based on current trends) followed by an acceleration in H2 2014, which assumes Eylea receives priority review for DME."
  • New EPS targets for FY14/15/16: $9.89/$14.35/$16.19.
  • Buy rating maintained.
  • Price target cut to $353 from $355.
Comments (2)
  • W121amg
    , contributor
    Comments (43) | Send Message
     
    Really a $2 cut on a $300 stock? They must have been bored today.
    6 Nov 2013, 02:44 PM Reply Like
  • gautamde
    , contributor
    Comments (18) | Send Message
     
    5% slide of stock price just for a $2 cut? There must be some other concern, though Jim Cramer and Goldman both maintain a BUY rating!
    6 Nov 2013, 03:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs